HUP0104018A3 - Pharmaceutical compositions containing antagonists of nr2b subtype of nmda receptor for treating neurological disorders - Google Patents
Pharmaceutical compositions containing antagonists of nr2b subtype of nmda receptor for treating neurological disordersInfo
- Publication number
- HUP0104018A3 HUP0104018A3 HU0104018A HUP0104018A HUP0104018A3 HU P0104018 A3 HUP0104018 A3 HU P0104018A3 HU 0104018 A HU0104018 A HU 0104018A HU P0104018 A HUP0104018 A HU P0104018A HU P0104018 A3 HUP0104018 A3 HU P0104018A3
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- neurological disorders
- nmda receptor
- treating neurological
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23777000P | 2000-10-02 | 2000-10-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0104018D0 HU0104018D0 (en) | 2001-12-28 |
HUP0104018A2 HUP0104018A2 (hu) | 2002-07-29 |
HUP0104018A3 true HUP0104018A3 (en) | 2004-04-28 |
Family
ID=22895086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104018A HUP0104018A3 (en) | 2000-10-02 | 2001-10-01 | Pharmaceutical compositions containing antagonists of nr2b subtype of nmda receptor for treating neurological disorders |
Country Status (13)
Country | Link |
---|---|
US (3) | US7019016B2 (hu) |
EP (1) | EP1199068B1 (hu) |
JP (1) | JP2002161052A (hu) |
KR (1) | KR100430539B1 (hu) |
AT (1) | ATE350103T1 (hu) |
AU (1) | AU7730401A (hu) |
CA (1) | CA2357929A1 (hu) |
DE (1) | DE60125681T2 (hu) |
ES (1) | ES2276750T3 (hu) |
HU (1) | HUP0104018A3 (hu) |
IL (1) | IL145584A0 (hu) |
NZ (1) | NZ514554A (hu) |
ZA (1) | ZA200107951B (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
JP2004537526A (ja) * | 2001-06-12 | 2004-12-16 | メルク エンド カムパニー インコーポレーテッド | 片頭痛の治療又は予防用nr2b受容体拮抗薬 |
US6743921B2 (en) * | 2002-01-24 | 2004-06-01 | Dsm Catalytica Pharmaceuticals, Inc. | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds |
US6855735B2 (en) * | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
CA2505788A1 (en) * | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
SE526255C2 (sv) * | 2003-03-14 | 2005-08-09 | Sandvik Intellectual Property | Verktyg och indexerbart skär för finsvarvning av rotationssymmetriska spår i arbetsstycken |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
KR20210107137A (ko) | 2008-04-21 | 2021-08-31 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
CA2722776A1 (en) * | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
US8648198B2 (en) | 2011-01-19 | 2014-02-11 | Cold Spring Harbor Laboratory | Phenylethanolamine-based NMDA receptor antagonists |
JP6084931B2 (ja) * | 2011-01-20 | 2017-02-22 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
KR101705448B1 (ko) | 2015-05-18 | 2017-02-09 | 허동길 | 애완동물용 물통 |
EP3471725A4 (en) | 2016-06-16 | 2020-01-22 | Cutispharma, Inc. | COMPOSITION AND METHOD FOR SUSPENDING A PROTON PUMP INHIBITOR |
US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5710168A (en) * | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
KR100224961B1 (ko) * | 1994-08-18 | 1999-10-15 | 디. 제이. 우드 | 신경보호성 3-(피페리디닐-1)-크로만-4,7-디올 및 1-(4-하이드로페닐)-2-(피페리디닐-1)-알칸올 유도체 |
DK0843661T3 (da) * | 1995-08-11 | 2002-07-22 | Pfizer | (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat |
TW450807B (en) * | 1995-09-15 | 2001-08-21 | Pfizer | Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents |
ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610736B (en) * | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
AU1463997A (en) * | 1995-12-22 | 1997-07-17 | Acea Pharmaceuticals, Inc. | Subtype-selective nmda receptor ligands and the use thereof |
ZA9610741B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
EP0787493A1 (en) * | 1996-02-03 | 1997-08-06 | F. Hoffmann-La Roche Ag | Tetrahydroisoquinoline derivatives |
KR200153170Y1 (ko) * | 1997-08-30 | 1999-08-02 | 정몽규 | 볼죠인트구조 |
GB9804886D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
GB9804885D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
PE20000728A1 (es) * | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
US20010007872A1 (en) * | 1998-10-01 | 2001-07-12 | Frank S. Menniti | Method of treating acute, chronic and/or neuropathic pain |
IL145584A0 (en) | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
-
2001
- 2001-09-24 IL IL14558401A patent/IL145584A0/xx unknown
- 2001-09-27 ZA ZA200107951A patent/ZA200107951B/xx unknown
- 2001-09-28 AU AU77304/01A patent/AU7730401A/en not_active Abandoned
- 2001-09-28 DE DE60125681T patent/DE60125681T2/de not_active Expired - Fee Related
- 2001-09-28 ES ES01308295T patent/ES2276750T3/es not_active Expired - Lifetime
- 2001-09-28 AT AT01308295T patent/ATE350103T1/de not_active IP Right Cessation
- 2001-09-28 EP EP01308295A patent/EP1199068B1/en not_active Expired - Lifetime
- 2001-09-28 CA CA002357929A patent/CA2357929A1/en not_active Abandoned
- 2001-09-29 KR KR10-2001-0060916A patent/KR100430539B1/ko not_active IP Right Cessation
- 2001-10-01 HU HU0104018A patent/HUP0104018A3/hu unknown
- 2001-10-01 NZ NZ514554A patent/NZ514554A/en unknown
- 2001-10-02 JP JP2001306254A patent/JP2002161052A/ja active Pending
- 2001-10-02 US US09/969,317 patent/US7019016B2/en not_active Expired - Fee Related
- 2001-10-02 US US09/969,318 patent/US6958351B2/en not_active Expired - Fee Related
-
2004
- 2004-04-09 US US10/821,526 patent/US20040192763A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040192763A1 (en) | 2004-09-30 |
US20040162312A1 (en) | 2004-08-19 |
JP2002161052A (ja) | 2002-06-04 |
AU7730401A (en) | 2002-04-11 |
EP1199068B1 (en) | 2007-01-03 |
EP1199068A3 (en) | 2003-06-18 |
US6958351B2 (en) | 2005-10-25 |
EP1199068A2 (en) | 2002-04-24 |
US7019016B2 (en) | 2006-03-28 |
ATE350103T1 (de) | 2007-01-15 |
HUP0104018A2 (hu) | 2002-07-29 |
HU0104018D0 (en) | 2001-12-28 |
NZ514554A (en) | 2004-10-29 |
KR20020027203A (ko) | 2002-04-13 |
ES2276750T3 (es) | 2007-07-01 |
DE60125681D1 (de) | 2007-02-15 |
US20020072538A1 (en) | 2002-06-13 |
KR100430539B1 (ko) | 2004-05-10 |
DE60125681T2 (de) | 2007-10-04 |
ZA200107951B (en) | 2003-04-29 |
IL145584A0 (en) | 2002-06-30 |
CA2357929A1 (en) | 2002-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104018A3 (en) | Pharmaceutical compositions containing antagonists of nr2b subtype of nmda receptor for treating neurological disorders | |
IL152230A0 (en) | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor | |
HK1047580B (zh) | 在糖尿病治療中作為糖皮質激素受體對抗劑的二苯並吡喃 | |
HUP0103558A3 (en) | Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury | |
HUP0200264A2 (en) | Use of estrogen agonists/antagonists for producing pharmaceutical compositions suitable for the treatment of cancers | |
IL157815A0 (en) | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | |
HUP0105079A3 (en) | Indole derivatives and their use as mcp-1 antagonists, process for preparation of the compounds and medicaments containing them | |
HUP0200139A3 (en) | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists, process for their preparation and pharmaceutical compositions containing them | |
IL146871A0 (en) | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | |
HUP0301167A3 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0003386A3 (en) | Use of crf antagonists for the preparation of pharmaceutical compositions treating depression, cardiovascular diseases | |
HUP0100120A3 (en) | Pharmaceutical compositions comprising estrogen agonists/antagonists suitable for treating conditions responsive to estrogen | |
HUP0303724A3 (en) | Chemokine receptors inhibitor bipiperidinyl-derivatives and pharmaceutical compositions containing them and process for preparation of the compounds | |
EP1223938A4 (en) | TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF COMPOUNDS OF 5-HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS / ALPHA-2 ADRENOZEPTORANTAGONISTS | |
HUP0202399A3 (en) | Use of dopamine d3 receptor ligands for producing pharmaceutical compositions for treating kidney disorders | |
HUP0203836A3 (en) | 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use | |
HUP0103767A3 (en) | Use of estrogen agonist/antagonist for preparation of pharmaceutical compositions available for treating osteoarthritis | |
IL147977A0 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain | |
WO2000072837A3 (en) | Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives | |
HUP0400349A3 (en) | Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them | |
HUP0200284A3 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them | |
HUP0104085A3 (en) | Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension | |
HUP0201710A2 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor, process for producing them and pharmaceutical compositions containing them | |
HUP0203976A3 (en) | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them | |
HUP0300694A3 (en) | Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |